Form 8-K - Current report:
SEC Accession No. 0001641172-25-018256
Filing Date
2025-07-08
Accepted
2025-07-08 17:29:11
Documents
21
Period of Report
2025-07-08
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 51099
2 EX-4.1 ex4-1.htm EX-4.1 143361
3 EX-5.1 ex5-1.htm EX-5.1 17368
4 EX-10.1 ex10-1.htm EX-10.1 270506
5 EX-10.2 ex10-2.htm EX-10.2 206925
6 EX-99.1 ex99-1.htm EX-99.1 13635
7 GRAPHIC ex5-1_001.jpg GRAPHIC 13708
8 GRAPHIC ex10-2_001.jpg GRAPHIC 11905
9 GRAPHIC ex10-2_002.jpg GRAPHIC 29425
  Complete submission text file 0001641172-25-018256.txt   1131555

Data Files

Seq Description Document Type Size
10 XBRL SCHEMA FILE lixt-20250708.xsd EX-101.SCH 3784
11 XBRL DEFINITION FILE lixt-20250708_def.xml EX-101.DEF 26650
12 XBRL LABEL FILE lixt-20250708_lab.xml EX-101.LAB 36768
13 XBRL PRESENTATION FILE lixt-20250708_pre.xml EX-101.PRE 25274
23 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5794
Mailing Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733
Business Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733 310 203 2902
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Filer) CIK: 0001335105 (see all company filings)

EIN.: 202903526 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39717 | Film No.: 251111799
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)